CY1110844T1 - MULTIPLE PIPES FOR CD20 - Google Patents

MULTIPLE PIPES FOR CD20

Info

Publication number
CY1110844T1
CY1110844T1 CY20101100951T CY101100951T CY1110844T1 CY 1110844 T1 CY1110844 T1 CY 1110844T1 CY 20101100951 T CY20101100951 T CY 20101100951T CY 101100951 T CY101100951 T CY 101100951T CY 1110844 T1 CY1110844 T1 CY 1110844T1
Authority
CY
Cyprus
Prior art keywords
polypeptide preparations
antigen
antibody
antibodies
multiple pipes
Prior art date
Application number
CY20101100951T
Other languages
Greek (el)
Inventor
Francis J Carr
Stephen Williams
Stephen D Gillies
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04764037A external-priority patent/EP1654287B1/en
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1110844T1 publication Critical patent/CY1110844T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση αναφέρεται σε πολυπεπτιδικά σκευάσματα, τα οποία προσδένουν το CD20 αντιγόνο, συγκεκριμένα το CD20 αντιγόνο του ανθρώπου. Τα πολυπεπτιδικά σκευάσματα έχουν τη βιολογική δράση των γνωστών αντι-CD20 αντισωμάτων, όπως είναι το 2Β8 ή το Leu16, παρουσιάζουν όμως μειωμένη ανοσογονικότητα σε σύγκριση με την αντίστοιχη των μη τροποποιημένων μορίων. Τα πολυπεπτιδικά σκευάσματα περιλαμβάνουν χιμαιρικά αντισώματα, τμήματα αντισωμάτων, και πρωτεΐνες σύντηξης ενός αντισώματος ή τμήματος αντισώματος με μια κυτταροκίνη.The invention relates to polypeptide preparations which bind the CD20 antigen, in particular the human CD20 antigen. Polypeptide preparations have the biological activity of known anti-CD20 antibodies, such as 2B8 or Leu16, but show reduced immunogenicity compared to that of unmodified molecules. Polypeptide preparations include chimeric antibodies, antibody fragments, and fusion proteins of an antibody or antibody fragment with a cytokine.

CY20101100951T 2003-08-14 2010-10-22 MULTIPLE PIPES FOR CD20 CY1110844T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03018480 2003-08-14
US52017103P 2003-11-14 2003-11-14
EP04764037A EP1654287B1 (en) 2003-08-14 2004-08-16 Cd20-binding polypeptide compositions

Publications (1)

Publication Number Publication Date
CY1110844T1 true CY1110844T1 (en) 2015-06-10

Family

ID=34196134

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100951T CY1110844T1 (en) 2003-08-14 2010-10-22 MULTIPLE PIPES FOR CD20

Country Status (2)

Country Link
CY (1) CY1110844T1 (en)
DE (1) DE602004028631D1 (en)

Also Published As

Publication number Publication date
DE602004028631D1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
CY1121206T1 (en) ANTIBODIES AGAINST CD20 WITH INCREASED RELATION ASSOCIATION TO FC RECEPTOR AND OPERATOR OPERATION
WO2005016969A3 (en) Cd20-binding polypeptide compositions
CY1123400T1 (en) HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND USES
CY1118693T1 (en) ANTI-ACTIVE AIDS AND USE OF THESE
CY1119755T1 (en) Proteins bound to human C-FMS antigen
CY1118979T1 (en) ANTIBODIES DIRECTED AGAINST HER-3 AND USE OF THESE
CY1118928T1 (en) ANTI-NO40 ANTIBODIES AND METHODS OF USE
CY1116167T1 (en) PHARMACEUTICAL COMPOSITIONS GUIDED ON ERB-B1
ATE509032T1 (en) CHIMERIZED GM-CSF ANTIBODIES
CY1118709T1 (en) ANTIGENIC Peptides of the Stimulating Colony Stimulating Factor (GM-CSF) AND ANTIBODIES FOR TON GM-CSF
CO6231038A2 (en) UNION PROTEINS, INCLUDING ANTIBODIES DERIVED FROM ANTIBODY AND ANTIBODY FRAGMENTS THAT SPECIFICALLY JOIN CD154 AND ITS USES
CY1114584T1 (en) RECOVERABLE VACCINES AND USE OF THESE
BRPI0411854A (en) protein vehicles for vaccines
ATE455127T1 (en) HUMAN ANTI-HUMAN CD3 BINDING MOLECULES
CR9236A (en) MOLECULAS OF UNION TO THE ANTIGEN THAT FIX EGER, VECTORS THAT CODE THEM AND USES OF THE SAME
CY1112446T1 (en) Antigen-based therapeutic substances with enhanced action of ADCC
UA93855C2 (en) Neutralizing epitope-based growth enhancing vaccine
CY1114639T1 (en) CHEMICAL SINGLE-DIMENSIONAL HYBRID HYBRIDS
CY1113326T1 (en) HUMAN ANTIBODIES THAT CONNECT HUMAN IL-12 AND ITS PRODUCTION METHODS
DK1572087T3 (en) Antibodies with cancer antigen TMEFF2 and applications thereof
CY1115927T1 (en) CATALOGS AGAINST TRAGED TRADE CTF-611
CY1120326T1 (en) ANTI-P-SELECTIN ANTIBODIES AND METHODS FOR USE AND IDENTIFICATION
MX2021010281A (en) Antigen binding proteins that bind bcma.
CY1116756T1 (en) AIMOCYANINE AND CODES FOR THIS NUCLEAR ACID SEQUENCE
CY1110844T1 (en) MULTIPLE PIPES FOR CD20